ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6 - PubMed (original) (raw)
ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6
Youn Soo Choi et al. Immunity. 2011.
Abstract
The nature of follicular helper CD4(+) T (Tfh) cell differentiation remains controversial, including the minimal signals required for Tfh cell differentiation and the time at which Tfh cell differentiation occurs. Here we determine that Tfh cell development initiates immediately during dendritic cell (DC) priming in vivo. We demonstrate that inducible costimulator (ICOS) provides a critical early signal to induce the transcription factor Bcl6, and Bcl6 then induces CXCR5, the canonical feature of Tfh cells. Strikingly, a bifurcation between Tfh and effector Th cells was measurable by the second cell division of CD4(+) T cells, at day 2 after an acute viral infection: IL2Rα(int) cells expressed Bcl6 and CXCR5 (Tfh cell program), whereas IL2Rα(hi) cells exhibited strong Blimp1 expression that repressed Bcl6 (effector Th cell program). Virtually complete polarization between Bcl6(+) Tfh cells and Blimp1(+) effector Th cell populations developed by 72 hr, even without B cells. Tfh cells were subsequently lost in the absence of B cells, demonstrating a B cell requirement for maintenance of Bcl6 and Tfh cell commitment via sequential ICOS signals.
Copyright © 2011 Elsevier Inc. All rights reserved.
Figures
Figure 1. Bcl6+CXCR5+ Tfh cell differentiation occurs within 72 hours in vivo
(A–D) LCMV-specific SM CD4+ T cells were transferred into B6 mice that were subsequently infected with LCMV. (A) Bcl6+CXCR5+ Tfh cells analyzed 7 days post-infection (p.i.) (“d7”) vs. naïve (“N”, CD44loCD62hi) CD4+ T cells of uninfected control mice. (B) Bcl6 protein expression in d7 SM as Δ MFI (e.g. Bcl6 MFITfh - Bcl6 MFInaiveCD4). (C) Bcl6+CXCR5+ Tfh cells, 3 and 4 days p.i. (“d3”, “d4”). “N”, uninfected mice. FACS plot shows SM CD4+ T cells. (D) Increase in SM CXCR5 MFI compared to that of naive (CD44loCD62hi) CD4+ T cells of uninfected mice. (E–H) Day 3 and 4 after LCMV infection, PD-1 (E) and CD69 (F) co-expression with CXCR5 on SM CD4+ T cells. (G) PD-1 and (H) CD69 MFIs of CXCR5+ SM vs. CXCR5− SM. Data are representative of three or more independent experiments; n = 4 per time point for all panels. *** P<0.001.
Figure 2. Early Bcl6+CXCR5+ Tfh cell differentiation is B cell-independent and does not require SAP- or CD40L–mediated signals
(A) Naïve _Sh2d1a_−/− or WT SM CD4+ T cells were transferred into B6 mice subsequently infected with LCMV. Bcl6+CXCR5+ Tfh cell differentiation analyzed at 3 and 4 days p.i. FACS plots show _Sh2d1a_−/− SM and gates identify Bcl6+CXCR5+ Tfh cells. (B) WT SM CD4+ T cells were transferred into either B6 or _Cd40_−/− mice subsequently infected with LCMV. Tfh cell differentiation was analyzed as shown in (A). (C, D) SM CD4+ T cells were transferred into B6 or B cell-deficient (µMT) mice, infected with LCMV, and the CD4+ T cell response was analyzed 7 days later. (C) SM CD4+ T cells are shown. Gate indicates SLAMloCXCR5hi Tfh cells. (D) SM cells are shown and gates identify Bcl6+CXCR5+ Tfh cells. Bcl6 protein calculated Δ MFI (e.g., Bcl6 MFITfh - Bcl6 MFInaiveCD4). (E, H) SM CD4+ T cells were transferred into B6 and µMT (or MD4-µMT. B def.) mice. Mice were then infected with LCMV and analyzed 3 (E) and 4 (H) days p.i. FACS plots show total SM cells, and gates identify Bcl6+CXCR5+ Tfh cells. Data are a composite of 3 or more independent experiments (n=15–16 per group for day 3, n=17–20 per group for day 4). (F, G) LCMV Gp61 peptide pulsed DCs were activated in vitro with LPS and transferred into B6 mice that had received naïve SM CD4+ T cells. SM were analyzed 4 days after DC immunization. (F)Left, SM CD4+ T cells in DC immunized (red line) vs. unimmunized mice (gray filled) compared to that of endogenous naïve (CD44lo) CD4+ T cells in DC immunized mice (black line). Right, CXCR5 MFIs calculated. Day 4 SM (“day4”) vs. SM in unimmunized mice (“N”). (G) Bcl6+CXCR5+ Tfh cells. (A-D, F and G) Data are representative of two independent experiments. n = 4 per group. n.s., no statistically significant difference (P>>0.05). *P<0.05, ***P<0.001.
Figure 3. Early Tfh cell commitment requires ICOS signals for Bcl6 expression
WT or _Icos_−/− SM CD4+ T cells were transferred into B6 mice subsequently infected with LCMV. (A, B) Bcl6+CXCR5+ Tfh cell development was analyzed 3 and 4 days p.i. by FACS (A) and quantified (B). (C) Bcl6 protein expression was quantified in WT CXCR5+ SM and WT CXCR5 SM vs. _Icos_−/− SM CD4+ T cells. (D) PD-1 expression on WT and _Icos_−/− SM CD4+ T cells. (E)Left, CXCR5 expression on WT (black) and _Icos_−/− (red) SM CD4+ T cells, compared to isotype control (gray filled). Right, CXCR5 MFIs. Data are representative of three independent experiments; n = 4 per group. ***P<0.001.
Figure 4. ICOS-dependent Tfh cell maintenance and germinal center formation
B6 and _Icos_−/− mice were infected with vaccinia virus (VACV). Mice were analyzed 8 days p.i. (A–D) and 12 days p.i. (E–G). (A) Representative FACS plots of germinal center B cells (Fas+PNA+). Total B220+ B cells are shown. Right, GC B cells were quantified as % of total B cells. (B) Representative FACS plots of WT and _Icos_−/− polyclonal Tfh cells. Activated CD4+ T cells (CD44hiCD62Llo) are shown and gates identify SLAMloCXCR5+ Tfh cells. Tfh cell frequencies (% of activated CD4+ T cells (CD44hiCD62Llo)) and CXCR5 MFIs were quantified. (C) Representative FACS plots of WT and _Icos_−/− polyclonal GC Tfh cells. Activated CD4+ T cells (CD44hiCD62Llo) are shown and gates identify GL7+CXCR5hi GC Tfh cells. GC Tfh cell frequencies were quantified (% of activated CD4+ T cells (CD44hiCD62Llo)). (D) Representative FACS plots of Bcl6 expression by CD4+ T cells in B6 and _Icos_−/− mice. Bcl6+CXCR5+ Tfh cells were quantified (% of activated CD4+ T cells). Tfh cells (E), GC Tfh cells (F), and germinal center B cells (G) were analyzed 12 days p.i., as for day 8 (A–C). Data are representative of two independent experiments for day 8 and day 12; n = 4 per group. (H–K) B6 mice were infected with VACV and treated with anti-ICOSL (αICOSL) or isotype control mAb at day 3, 5, and 7 as schematically shown in Figure S4E. Tfh cells (H), GC Tfh cells (I), Bcl6 expression (J), and GC B cells (K) were analyzed 8 days p.i. “C” = isotype control mAb treated mice. “αICOSL” = anti-ICOSL treated mice. “N” = naïve uninfected mice. n = 5–6 per group. Data are representative of two independent experiments. *P<0.05, **P<0.01, ***P<0.001.
Figure 5. ICOS → Bcl6 → CXCR5
(A–E) Blimp1 expressing (Prdm1-RV+, GFP+) and non-transduced (GFP) SM CD4+ T cells were transferred into the same (A) or separate (B–E) B6 recipient mice. (A) SM CD4+ T cells at day 4 after LCMV infection. (B) WT SM vs. Prdm1-RV+ SM CD4+ T cell expansion (% of total CD4+ T cells). (C, D) CXCR5 expression by Prdm1-RV+ SM and WT SM, day 4 p.i. (C) Representative FACS plots showing WT (GFP) and Prdm1-RV+ (GFP+). Gates identify CXCR5+Bcl6+ SM. (D) Quantitation of CXCR5+ and CXCR5+Bcl6+ SM. (E) CXCR5+ SM and Bcl6+CXCR5+ Tfh cell frequencies day 3 p.i. (F, G) Bcl6 shRNA-RV+ (GFP+Ametrine+) and non-transduced (GFP−Ametrine) SM CD4+ T cells were transferred into separate B6 recipient mice subsequently infected with LCMV. (F) SM CD4+ T cell expansion, day 4 p.i. (% of total CD4+ T cells). (G) Representative FACS plots of CXCR5 and Bcl6 expression by WT SM and Bcl6 shRNA+ SM CD4+ T cells. Total SM cells are shown and gates identify Bcl6+CXCR5+ SM. Data are representative of three (A–E) and two (F–G) independent experiments; n = 4 per group per time point. **P<0.01, ***P<0.001.
Figure 6. Rapid Bcl6 versus Blimp-1 bifurcation of CD4+ T cell differentiation in vivo
(A) Blimp1 and CXCR5 expression by Blimp1-YFP BAC tg SM CD4+ T cells was analyzed at 8 days p.i. in B6 recipient mice. Gates identify Blimp1+CXCR5− effector Th cells and Blimp1−CXCR5+ Tfh cells. (B)Left, Bcl6 expression in Blimp1+CXCR5− (gray filled) vs. Blimp1CXCR5+ (black line) SM CD4+ T cells. Right, Bcl6 MFIs. (C) Day 3 p.i., analysis of Blimp1, Bcl6, and CXCR5 expression by Blimp1-YFP BAC Tg SM CD4+ T cells in B6 recipients. Representative FACS plots of SM cells from LCMV infected (“Day3”) and uninfected (“Naïve”) recipients are shown. CXCR5 and Bcl6 expression by Blimp1+ vs. Blimp1− SM CD4+ T cells were quantified. “Ctrl” = isotype control stain. (D) MD4-µMT recipient mice of Blimp1-YFP BAC tg SM CD4+ T cells, day 3 p.i. Representative FACS plot of SM cells and CXCR5 quantitation. (E–G) Blimp1-YFP SM CD4+ T cells were transferred into B6 recipients and analyzed for IL2Rα expression 3 days after LCMV infection. IL2Rαhi vs. IL2Rαlo SM CD4+ T cells are identified in co-stains with CXCR5 (E), Bcl6 (F), and Blimp1 (G). Data in all panels are representative of three or more independent experiments; n = 3–4 per group. **P<0.01, ***P<0.001.
Figure 7. Tfh versus effector Th cells are distinguishable by the second cell division, in association with differential early IL-2Rα expression levels
Early virus-specific Tfh vs. effector Th cell differentiation was analyzed at 48 hrs after acute LCMV infection. (A) Representative FACS plots of SM CD4+ T cells from LCMV infected (“Day 2”) and uninfected (“Naïve”) mice. Gates identify IL2RαhiCXCR5lo vs. IL2RαintCXCR5hi SM CD4+ T cells. (B) CXCR5 expression by IL2Rαhi (black) vs. IL2Rαint (red) SM CD4+ T cells. Isotype control = gray filled histogram. (C) Bcl6 expression by IL2Rαhi vs. IL2Rαint SM CD4+ T cells. (D) Expression of IL2Rα and CXCR5 by SM CD4+ T cells in MD4-µMT recipients, day 2 p.i. (E) Bcl6 expression by SM CD4+ T cells in MD4-µMT recipients, day 2 p.i. (F) IL2Rα and Blimp1 expression by Blimp1-YFP SM CD4+ T cells in B6 recipients, day 2 p.i. Representative SM CD4+ T cell FACS plot and quantitation are shown. (G) IL2R α expression (MFI) by SM CD4+ T cell populations gated in (F). (H) Bcl6 expression by SM CD4+ T cells in B6 recipients at day 2 p.i. Gates identify IL2Rαhi vs. IL2Rαint SM CD4+ T cells. Bcl6 protein expression (MFI) by each population was calculated. (I, J) CFSE-labeled SM CD4+ T cells were transferred into B6 recipient mice subsequently infected with LCMV. Cell divisions and differentiation were analyzed at day 2 p.i. (I) Cell divisions. Gray filled histogram = SM CD4+ T cells in uninfected mice. (J) Representative FACS plots are shown of SM CD4+ T cells that have undergone 2 (left) and 3 (right) cell divisions. Gates identify IL2RαhiBcl6− and IL2RαintBcl6+ SM CD4+ T cells. Data in all panels are representative of three or more independent experiments; n = 3–4 per group. **P<0.01, ***P<0.001.
Comment in
- A fine romance: T follicular helper cells and B cells.
King C. King C. Immunity. 2011 Jun 24;34(6):827-9. doi: 10.1016/j.immuni.2011.06.007. Immunity. 2011. PMID: 21703537
Similar articles
- CD25(+) Bcl6(low) T follicular helper cells provide help to maturing B cells in germinal centers of human tonsil.
Li H, Pauza CD. Li H, et al. Eur J Immunol. 2015 Jan;45(1):298-308. doi: 10.1002/eji.201444911. Epub 2014 Oct 27. Eur J Immunol. 2015. PMID: 25263533 Free PMC article. - Bcl6 and Maf cooperate to instruct human follicular helper CD4 T cell differentiation.
Kroenke MA, Eto D, Locci M, Cho M, Davidson T, Haddad EK, Crotty S. Kroenke MA, et al. J Immunol. 2012 Apr 15;188(8):3734-44. doi: 10.4049/jimmunol.1103246. Epub 2012 Mar 16. J Immunol. 2012. PMID: 22427637 Free PMC article. - Circulating precursor CCR7(lo)PD-1(hi) CXCR5⁺ CD4⁺ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure.
He J, Tsai LM, Leong YA, Hu X, Ma CS, Chevalier N, Sun X, Vandenberg K, Rockman S, Ding Y, Zhu L, Wei W, Wang C, Karnowski A, Belz GT, Ghali JR, Cook MC, Riminton DS, Veillette A, Schwartzberg PL, Mackay F, Brink R, Tangye SG, Vinuesa CG, Mackay CR, Li Z, Yu D. He J, et al. Immunity. 2013 Oct 17;39(4):770-81. doi: 10.1016/j.immuni.2013.09.007. Immunity. 2013. PMID: 24138884 - Transcriptional regulation of follicular T-helper (Tfh) cells.
Liu X, Nurieva RI, Dong C. Liu X, et al. Immunol Rev. 2013 Mar;252(1):139-45. doi: 10.1111/imr.12040. Immunol Rev. 2013. PMID: 23405901 Free PMC article. Review. - Follicular Helper T Cells.
Vinuesa CG, Linterman MA, Yu D, MacLennan IC. Vinuesa CG, et al. Annu Rev Immunol. 2016 May 20;34:335-68. doi: 10.1146/annurev-immunol-041015-055605. Epub 2016 Feb 22. Annu Rev Immunol. 2016. PMID: 26907215 Review.
Cited by
- Development of T follicular helper cell-independent nanoparticle vaccines for SARS-CoV-2 or HIV-1 by targeting ICOSL.
Zhang Y, Chen A, Li D, Yuan Q, Zhu A, Deng J, Wang Y, Liu J, Liang C, Li W, Fang Q, Xie J, Zhang X, Zhang X, Zhang Y, Chen R, Pan T, Zhang H, He X. Zhang Y, et al. NPJ Vaccines. 2024 Sep 28;9(1):176. doi: 10.1038/s41541-024-00971-4. NPJ Vaccines. 2024. PMID: 39341822 Free PMC article. - Neutralization activity in chronic HIV infection is characterized by a distinct programming of follicular helper CD4 T cells.
Moysi E, Sharma AA, O'Dell S, Georgakis S, Del Rio Estrada PM, Torres-Ruiz F, Navarro MG, Villalobos YAL, Rios SA, Reyes-Teran G, Beddall MH, Ko SH, Belinky F, Orfanakis M, de Leval L, Enriquez AB, Buckner CM, Moir S, Doria-Rose N, Boritz E, Mascola JR, Sekaly RP, Koup RA, Petrovas C. Moysi E, et al. bioRxiv [Preprint]. 2024 Aug 3:2024.07.31.605954. doi: 10.1101/2024.07.31.605954. bioRxiv. 2024. PMID: 39131331 Free PMC article. Preprint. - Mutations in Ras homolog family member A in patients with peripheral T-cell lymphoma and implications for personalized medicine.
Hu L, Zhang X, Zang S. Hu L, et al. Cancer Biol Med. 2024 Aug 9;21(9):754-68. doi: 10.20892/j.issn.2095-3941.2024.0132. Cancer Biol Med. 2024. PMID: 39119774 Free PMC article. Review. - Exploring the Role of PD-1 in the Autoimmune Response: Insights into Its Implication in Systemic Lupus Erythematosus.
Sagrero-Fabela N, Chávez-Mireles R, Salazar-Camarena DC, Palafox-Sánchez CA. Sagrero-Fabela N, et al. Int J Mol Sci. 2024 Jul 15;25(14):7726. doi: 10.3390/ijms25147726. Int J Mol Sci. 2024. PMID: 39062968 Free PMC article. Review. - Reciprocal regulation of T follicular helper cells and dendritic cells drives colitis development.
Bai X, Chen S, Chi X, Xie B, Guo X, Feng H, Wei P, Zhang D, Xie S, Xie T, Chen Y, Gou M, Qiao Q, Liu X, Jin W, Xu W, Zhao Z, Xing Q, Wang X, Zhang X, Dong C. Bai X, et al. Nat Immunol. 2024 Aug;25(8):1383-1394. doi: 10.1038/s41590-024-01882-1. Epub 2024 Jun 28. Nat Immunol. 2024. PMID: 38942990
References
- Akiba H, Takeda K, Kojima Y, Usui Y, Harada N, Yamazaki T, Ma J, Tezuka K, Yagita H, Okumura K. The role of ICOS in the CXCR5+ follicular B helper T cell maintenance in vivo. J Immunol. 2005;175:2340–2348. - PubMed
- Awasthi A, Kuchroo VK. Immunology. The yin and yang of follicular helper T cells. Science. 2009;325:953–955. - PubMed
- Bossaller L, Burger J, Draeger R, Grimbacher B, Knoth R, Plebani A, Durandy A, Baumann U, Schlesier M, Welcher AA, et al. ICOS deficiency is associated with a severe reduction of CXCR5+CD4 germinal center Th cells. J Immunol. 2006;177:4927–4932. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AI072543-04S1/AI/NIAID NIH HHS/United States
- R01 AI063107/AI/NIAID NIH HHS/United States
- R01 AI063107-06/AI/NIAID NIH HHS/United States
- R01 AI072543/AI/NIAID NIH HHS/United States
- R01 AI072543-05/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials